Recent Updates
Recently added Catalysts
ABBV Positive Sentiment Score: 85/100

AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility New state-of-the-art active pharmaceutical ingredient (API) facility will manufacture immunology, oncology and neuroscience medicines Facility...

Key Takeaway: AbbVie has begun construction on a new active pharmaceutical ingredient (API) manufacturing facility in North Chicago, Illinois, marking a significant step in its expansion efforts. The company plans to invest over $10 billion in U.S. manufacturing over the next decade, focusing on enhancing capabilities in immunology, oncology, and neuroscience. This facility will allow for the domestic production of certain APIs currently made overseas, furthering AbbVie's commitment to improving patient outcomes in the U.S. and around the world. The investment will also create additional jobs and strengthen AbbVie's existing manufacturing footprint in the region.

Market Sentiment Analysis

POSITIVE FACTORS

  • AbbVie is investing over $10 billion in U.S. manufacturing expansion.
  • The new facility will create new jobs and enhance local economies.
  • It supports domestic production of vital medications across multiple therapeutic areas.

Full Press Release Details

NORTH CHICAGO, Ill. , Sept. 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced the start of construction of its new active pharmaceutical ingredient (API) manufacturing plant in North Chicago, Illinois. This is a significant milestone in AbbVie's ongoing efforts to expand its U.S. manufacturing network, capabilities and capacity.
"Today's groundbreaking is an important milestone in AbbVie's ongoing campaign to accelerate biopharmaceutical innovation and manufacturing capabilities in the U.S.," said Azita Saleki-Gerhardt, Ph.D., executive vice president and chief operations officer, AbbVie. "Over the next decade, AbbVie plans to invest more than $10 billion in capital to add multiple new U.S. manufacturing plants and improve the lives of millions of patients in the U.S. and worldwide who depend on our medicines."
Active pharmaceutical ingredient manufacturing is a complex and multistep process that involves producing the active components responsible for medications' therapeutic effects. When completed, AbbVie's new North Chicago API facility will expand its chemical synthesis capabilities and enable AbbVie to bring API production for select products from Europe and Asia to the US to support domestic production of current and next generation neuroscience, immunology and oncology medicines.
With a presence in all 50 states and Puerto Rico, AbbVie employs 28,000 employees in the U.S. The previously announced $195 million investment in North Chicago will create new jobs and expand AbbVie's existing U.S. manufacturing footprint, which supports more than 6,000 American jobs across 11 manufacturing sites. This investment also furthers AbbVie's long-term commitment to Illinois, where it is headquartered and includes more than 11,000 employees who work to develop and manufacture innovative medicines for patients worldwide.
About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com . Follow @abbvie on LinkedIn, Facebook , Instagram , X (formerly Twitter) and YouTube.
Media: Investors:
Gabby Tarbert Liz Shea
(224) 244-0111 (847) 935-2211
[email protected] [email protected]

21 %

Frequently Asked Questions

When did AbbVie announce the construction of its new plant?

AbbVie announced the groundbreaking for its new API manufacturing plant on Sept. 29, 2025.

Where is AbbVie's new manufacturing plant located?

The new active pharmaceutical ingredient plant is located in North Chicago, Illinois.

How much is AbbVie investing in U.S. manufacturing?

AbbVie plans to invest over $10 billion in U.S. manufacturing over the next decade.

What will the new facility expand for AbbVie?

The new facility will enhance AbbVie's chemical synthesis capabilities for producing APIs.

How many jobs will the new plant create?

The investment will create new jobs, expanding AbbVie's existing U.S. manufacturing footprint.

Last updated: Sep 29, 2025